AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Paragon Banking Group PLC

Prospectus Feb 5, 2015

4701_prs_2015-02-05_24669045-7521-4b63-acaa-a2d4753c6688.html

Prospectus

Open in Viewer

Opens in native device viewer

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 1930E

Paragon Group Of Companies PLC

05 February 2015

The Paragon Group of Companies PLC

Publication of Supplement    

5 February 2015

The following supplement (the "Supplement") has been approved by the UK Listing Authority and is available for viewing:

Supplement dated 5 February 2015 to the Base Prospectus dated 23 October 2014 relating to The Paragon Group of Companies PLC £1,000,000,000 Euro Medium Term Note Programme.

Please read the disclaimer below "Disclaimer - Intended Addressees" before attempting to access this service, as your right to do so is conditional upon complying with the requirements set out below.

To view the Supplement, please follow the link below:

http://www.rns-pdf.londonstockexchange.com/rns/1930E_-2015-2-5.pdf

A copy of the Supplement will also be submitted to the National Storage Mechanism and will shortly be available for inspection at: www.morningstar.co.uk/uk/NSM.

For further information, please contact:

Investor Relations

The Paragon Group of Companies PLC

Address: 51 Homer Road

Solihull

West Midlands

B91 3QJ

Telephone: 0845 849 4003

Fax: 0207 786 8484

Email: [email protected]  

DISCLAIMER - INTENDED ADDRESSEES

This announcement is not for distribution in the United States.

Please note that the information contained in the Supplement may be addressed to and/or targeted at persons who are residents of particular countries (specified in the Supplement) only and is not intended for use and should not be relied upon by any person outside these countries and/or to whom the offer contained in the Supplement is not addressed. Prior to relying on the information contained in the Supplement you must ascertain from the Supplement whether or not you are part of the intended addressees of, and eligible to view, the information contained therein.

In particular, neither this announcement nor the Supplement shall constitute an offer to sell or the solicitation of an offer to buy securities in the United States or in any other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration, exemption from registration or qualification under the securities law of any such jurisdiction.

The securities described in the Supplement have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"). Subject to certain exceptions, the securities may not be offered, sold or delivered within the United States or to, or for the account or benefit of U.S. persons. The securities are being offered and sold outside of the United States in reliance on Regulation S of the Securities Act. There will be no public offering in the United States.

This information is provided by RNS

The company news service from the London Stock Exchange

END

PDISSUFIIFISESE

Talk to a Data Expert

Have a question? We'll get back to you promptly.